Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Corso, 1999, Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy., Haematologica, 84, 336 1998, Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group., J Clin Oncol, 16, 3832, 10.1200/JCO.1998.16.12.3832 Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies., Blood, 111, 2516, 10.1182/blood-2007-10-116129 Barlogie, 1986, High-dose melphalan with autologous bone marrow transplantation for multiple myeloma., Blood, 67, 1298, 10.1182/blood.V67.5.1298.1298 Bladé, 1998, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation., Br J Haematol, 102, 1115, 10.1046/j.1365-2141.1998.00930.x Martinez-Lopez, 2011, Long-term prognostic significance of response in multiple myeloma after stem cell transplantation., Blood, 118, 529, 10.1182/blood-2011-01-332320 Hajek, 2013, Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma., Br J Haematol, 163, 551, 10.1111/bjh.12563 Brüggemann, 2012, Has MRD monitoring superseded other prognostic factors in adult ALL?, Blood, 120, 4470, 10.1182/blood-2012-06-379040 Ho, 2013, Defining patient-specific risk in acute myeloid leukemia., J Clin Oncol, 31, 3857, 10.1200/JCO.2013.51.4307 Paiva, 2008, Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation., Blood, 112, 4017, 10.1182/blood-2008-05-159624 Rawstron, 2013, Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study., J Clin Oncol, 31, 2540, 10.1200/JCO.2012.46.2119 Martinelli, 2000, Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma., J Clin Oncol, 18, 2273, 10.1200/JCO.2000.18.11.2273 Martinez-Lopez, 2013, Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study., Br J Haematol, 163, 581, 10.1111/bjh.12576 Mitterer, 1999, The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients., Br J Haematol, 106, 737, 10.1046/j.1365-2141.1999.01603.x Puig, 2014, Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry., Leukemia, 28, 391, 10.1038/leu.2013.217 Martínez-Sánchez, 2008, Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response., Br J Haematol, 142, 766, 10.1111/j.1365-2141.2008.07263.x Paiva, 2011, Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma., J Clin Oncol, 29, 1627, 10.1200/JCO.2010.33.1967 Armand, 2013, Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma., Br J Haematol, 163, 123, 10.1111/bjh.12439 Faham, 2012, Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia., Blood, 120, 5173, 10.1182/blood-2012-07-444042 Gawad, 2012, Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia., Blood, 120, 4407, 10.1182/blood-2012-05-429811 Logan, 2013, Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia., Leukemia, 27, 1659, 10.1038/leu.2013.52 Vij, 2014, Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients., Clin Lymphoma Myeloma Leuk, 14, 131, 10.1016/j.clml.2013.09.013 Lahuerta, 2008, Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival., J Clin Oncol, 26, 5775, 10.1200/JCO.2008.17.9721 Mateos, 2010, Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial., Lancet Oncol, 11, 934, 10.1016/S1470-2045(10)70187-X Rosiñol, 2012, Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study., Blood, 120, 1589, 10.1182/blood-2012-02-408922 Mateos, 2013, Comparison of sequential vs. alternating administration of bortezomib, melphalan and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma patients: GEM2010mas65 Trial., Blood, 122, 403, 10.1182/blood.V122.21.403.403 Paiva, 2010, Analysis of immunophenotypic response by multiparameter flow cytometry in 516 myeloma patients included in three consecutive Spanish trials., Blood, 116, 1910, 10.1182/blood.V116.21.1910.1910 Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1., Blood, 117, 4691, 10.1182/blood-2010-10-299487 Paiva, 2012, High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma., Blood, 119, 687, 10.1182/blood-2011-07-370460 Sarasquete, 2005, Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry., Haematologica, 90, 1365 Mahindra, 2012, Latest advances and current challenges in the treatment of multiple myeloma., Nat Rev Clin Oncol, 9, 135, 10.1038/nrclinonc.2012.15 Palumbo, 2011, Multiple myeloma., N Engl J Med, 364, 1046, 10.1056/NEJMra1011442 Anderson, 2011, Oncogenomics to target myeloma in the bone marrow microenvironment., Clin Cancer Res, 17, 1225, 10.1158/1078-0432.CCR-10-3366 Attal, 2012, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma., N Engl J Med, 366, 1782, 10.1056/NEJMoa1114138 Badros, 2012, Lenalidomide in myeloma—a high-maintenance friend., N Engl J Med, 366, 1836, 10.1056/NEJMe1202819 McCarthy, 2012, Lenalidomide after stem-cell transplantation for multiple myeloma., N Engl J Med, 366, 1770, 10.1056/NEJMoa1114083 Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma., N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 Munshi, 2013, Minimal residual disease in multiple myeloma., J Clin Oncol, 31, 2523, 10.1200/JCO.2013.49.2124 Ladetto, 2010, Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma., J Clin Oncol, 28, 2077, 10.1200/JCO.2009.23.7172 Bakkus, 2004, Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma., Br J Haematol, 126, 665, 10.1111/j.1365-2141.2004.05120.x Puig, 2013, The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma., Ann Hematol, 92, 97, 10.1007/s00277-012-1566-3 van der Velden, 2003, Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects., Leukemia, 17, 1013, 10.1038/sj.leu.2402922 San-Miguel, 2013, New tools for diagnosis and monitoring of multiple myeloma., Am Soc Clin Oncol Educ Book, 33.e313 Frébet, 2011, A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma., Cytometry B Clin Cytom, 80, 176, 10.1002/cyto.b.20581 Flanders, 2013, Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity., Blood, 122, 1088, 10.1182/blood-2013-05-506170 Rawstron, 2008, Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders., Haematologica, 93, 431, 10.3324/haematol.11080 Zamagni, 2013, PET/CT is a useful tool for both refining the definition of complete response in multiple myeloma and detecting otherwise unrevealed progression during the follow-up of the disease: a single centre experience on 282 patients ASH Annual Meeting Abstracts., Blood, 122, 1936, 10.1182/blood.V122.21.1936.1936 Matsui, 2008, Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance., Cancer Res, 68, 190, 10.1158/0008-5472.CAN-07-3096 Reghunathan, 2013, Clonogenic multiple myeloma cells have shared stemness signature assocuated with patient survival., Oncotarget, 4, 1230, 10.18632/oncotarget.1145 Paiva, 2013, Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile., Blood, 122, 3591, 10.1182/blood-2013-06-510453